• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

马萨诸塞州在开始治疗阿片类药物使用障碍药物前后的牙科保健利用率:一项基于全州支付者索赔数据库的横断面研究。

Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross-sectional study of a state all-payer claims database.

机构信息

Department of Oral Health Policy and Epidemiology, Harvard School of Dental Medicine, Boston, Massachusetts, USA.

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

出版信息

J Public Health Dent. 2022 Sep;82(4):461-467. doi: 10.1111/jphd.12488. Epub 2021 Nov 23.

DOI:10.1111/jphd.12488
PMID:34816438
Abstract

BACKGROUND

Individuals with opioid use disorder (OUD) are at higher risk of poor oral health. Medication for opioid use disorder (MOUD) has been shown to improve outcomes for patients with OUD, but it is unknown how initiation of MOUD affects access to oral health services.

METHODS

This was a retrospective analysis of all individuals in the Massachusetts All-Payer Claims Database prescribed oral buprenorphine-naloxone or injectable naltrexone from 2013 to 2016. We evaluated dental utilization in the year before and after beginning MOUD. A logistic regression predicting dental utilization was conducted.

RESULTS

Among the 54,791 individuals, rates of dental utilization were low both before and after MOUD (10.5% and 10% with a dental visit, respectively). Of those who did not have a dental visit in the year before starting MOUD, 95.1% did not have a dental visit in the year after. Rates of various procedure types were comparable before and after MOUD. In a logistic regression, a prior dental visit was associated with 9.82 times the odds (95% CI 9.14-10.55) of having a dental visit after starting MOUD; increasing age, being prescribed naltrexone, having a mood disorder or HIV, year of initiation or being on Medicaid were also associated with having a dental visit. Male patients and those with Medicare or private insurance were less likely to have a dental visit.

CONCLUSIONS

Initiating MOUD did not substantially result in increased dental access or substantial changes in dental procedures received. Patients receiving treatment for OUD may require additional support to access dental care.

摘要

背景

患有阿片类药物使用障碍(OUD)的个体口腔健康状况较差的风险较高。已证明治疗阿片类药物使用障碍的药物(MOUD)可改善 OUD 患者的预后,但尚不清楚启动 MOUD 如何影响获得口腔健康服务的机会。

方法

这是对 2013 年至 2016 年期间在马萨诸塞州所有付费者索赔数据库中接受口服丁丙诺啡-纳洛酮或注射用纳曲酮治疗的所有个体进行的回顾性分析。我们评估了开始 MOUD 前后一年的牙科利用率。进行了预测牙科利用率的逻辑回归分析。

结果

在 54791 名患者中,MOUD 前后的牙科利用率均较低(分别为 10.5%和 10%有牙科就诊)。在开始 MOUD 前一年没有牙科就诊的患者中,95.1%在开始 MOUD 后一年没有牙科就诊。MOUD 前后各种程序类型的比率相当。在逻辑回归中,先前的牙科就诊与牙科就诊的可能性相关(95%CI 9.14-10.55)增加了 9.82 倍;年龄增加、开处方纳曲酮、患有心境障碍或 HIV、启动年份或参加医疗补助计划也与牙科就诊相关。男性患者和参加医疗保险或私人保险的患者不太可能进行牙科就诊。

结论

启动 MOUD 并未导致牙科就诊机会显著增加或接受的牙科程序发生实质性变化。接受 OUD 治疗的患者可能需要额外的支持才能获得牙科护理。

相似文献

1
Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross-sectional study of a state all-payer claims database.马萨诸塞州在开始治疗阿片类药物使用障碍药物前后的牙科保健利用率:一项基于全州支付者索赔数据库的横断面研究。
J Public Health Dent. 2022 Sep;82(4):461-467. doi: 10.1111/jphd.12488. Epub 2021 Nov 23.
2
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.在美国商业保险人群中,接受阿片类药物使用障碍治疗的个体中,可注射纳曲酮、口服纳曲酮和丁丙诺啡的使用和停药情况。
J Subst Abuse Treat. 2018 Feb;85:90-96. doi: 10.1016/j.jsat.2017.07.001. Epub 2017 Jul 3.
3
Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort.与阿片类药物使用障碍的不同药物治疗起始相关的自付支出和医疗保健利用:来自全国商业保险队列的研究结果。
J Subst Use Addict Treat. 2024 Apr;159:209281. doi: 10.1016/j.josat.2023.209281. Epub 2023 Dec 18.
4
Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit.住院或急诊就诊后开始治疗阿片类药物使用障碍时的阿片类药物过量。
JAMA Netw Open. 2024 Jul 1;7(7):e2423954. doi: 10.1001/jamanetworkopen.2024.23954.
5
Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.阿片类物质使用障碍及共病多种物质使用中丁丙诺啡与纳曲酮的疗效比较。
JAMA Netw Open. 2022 May 2;5(5):e2211363. doi: 10.1001/jamanetworkopen.2022.11363.
6
Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts.马萨诸塞州严重注射相关感染后治疗阿片类药物使用障碍的药物。
JAMA Netw Open. 2024 Jul 1;7(7):e2421740. doi: 10.1001/jamanetworkopen.2024.21740.
7
Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.医疗保险中阿片类药物使用障碍药物获取、使用和治疗结果的种族和民族差异。
J Subst Use Addict Treat. 2024 Feb;157:209271. doi: 10.1016/j.josat.2023.209271. Epub 2023 Dec 21.
8
Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.接受阿片类药物使用障碍药物治疗的女性的妊娠率。
J Gen Intern Med. 2024 Jun;39(8):1342-1348. doi: 10.1007/s11606-024-08689-8. Epub 2024 Feb 29.
9
Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.阿片类物质使用障碍患者中,美沙酮、丁丙诺啡和纳曲酮处方的心脏和死亡率结局差异。
J Clin Psychol. 2023 Dec;79(12):2869-2883. doi: 10.1002/jclp.23582. Epub 2023 Aug 16.
10
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.医疗保险受益人的远程医疗服务的接受情况、阿片类药物使用障碍药物的获得和保留情况,以及在 COVID-19 大流行之前和期间的药物治疗过量情况。
JAMA Psychiatry. 2022 Oct 1;79(10):981-992. doi: 10.1001/jamapsychiatry.2022.2284.